KRSA: KRSA-028 targets monthly subQ dosing, with first patient proof-of-concept due by Q1 2028
Lesedauer weniger als 1 min
KRSA-028 is designed as a monthly subQ, pyroglutamate-targeting amyloid shuttle, with preclinical design choices aimed at retaining plaque clearance while reducing safety risks. Healthy-volunteer data are targeted for mid-2027, with patient proof-of-concept by late 2027 or Q1 2028.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr